JOLYPHARMA

JOLYPHARMA has been active since 2001 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €952,385 and a net result of €93,466. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 88% of 5,007 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).